跳至主要内容
临床试验/NCT01243853
NCT01243853Unknown不适用

Alpha-galactosidase Enzyme and Irritable Bowel Syndrome

Verman Oy Ab2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2010年12月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
150
试验地点
2
主要终点
IBS symptom severity

研究概览

简要总结

The purpose of this study is to determine whether alpha-galactosidase enzyme is affective in alleviating the symptoms of irritable bowel syndrome (IBS).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of IBS according to Rome III criteria, additionally abdominal distension or flatulence the most disturbing symptom
  • Age 18-65 years
  • Colonoscopy conducted within the previous 5 years, finding macroscopically and histologically normal

排除标准

  • Organic GI disease. Treated (min. 1 year) coeliac disease patients, and subjects with known and treated lactose intolerance are allowed to participate
  • Malignancy
  • Significant gastrointestinal surgery
  • Clinically significant aberrancies in the screening-phase laboratory analyses
  • Changes in regular medication during the previous 4 weeks
  • Pregnancy or breast feeding
  • Other disease or state that based on the investigator's evaluation complicates the conduction of the intervention, i.e. alcoholism, dementia
  • Hereditary galactosemia

结局指标

主要结局

IBS symptom severity

时间窗: follow-up (4 months)

The IBS symptom severity score (IBS-SSS) questionnaire is used

次要结局

未报告次要终点

研究者

发起方
Verman Oy Ab
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验